 Survival Analysis
"Survival Analysis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
| Descriptor ID |
D016019
|
| MeSH Number(s) |
E05.318.740.998 N05.715.360.750.795 N06.850.520.830.998
|
| Concept/Terms |
Survival Analysis- Survival Analysis
- Analysis, Survival
- Analyses, Survival
- Survival Analyses
|
Below are MeSH descriptors whose meaning is more general than "Survival Analysis".
Below are MeSH descriptors whose meaning is more specific than "Survival Analysis".
This graph shows the total number of publications written about "Survival Analysis" by people in this website by year, and whether "Survival Analysis" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1989 | 0 | 1 | 1 | | 1990 | 0 | 13 | 13 | | 1991 | 0 | 8 | 8 | | 1992 | 0 | 9 | 9 | | 1993 | 0 | 11 | 11 | | 1994 | 0 | 12 | 12 | | 1995 | 2 | 13 | 15 | | 1996 | 1 | 16 | 17 | | 1997 | 1 | 15 | 16 | | 1998 | 0 | 16 | 16 | | 1999 | 0 | 31 | 31 | | 2000 | 1 | 30 | 31 | | 2001 | 0 | 32 | 32 | | 2002 | 1 | 35 | 36 | | 2003 | 0 | 50 | 50 | | 2004 | 0 | 54 | 54 | | 2005 | 1 | 47 | 48 | | 2006 | 0 | 59 | 59 | | 2007 | 0 | 51 | 51 | | 2008 | 2 | 47 | 49 | | 2009 | 0 | 48 | 48 | | 2010 | 1 | 46 | 47 | | 2011 | 2 | 42 | 44 | | 2012 | 0 | 44 | 44 | | 2013 | 0 | 30 | 30 | | 2014 | 0 | 44 | 44 | | 2015 | 0 | 37 | 37 | | 2016 | 1 | 42 | 43 | | 2017 | 3 | 59 | 62 | | 2018 | 3 | 49 | 52 | | 2019 | 0 | 43 | 43 | | 2020 | 0 | 32 | 32 | | 2021 | 1 | 25 | 26 | | 2022 | 1 | 3 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Survival Analysis" by people in Profiles.
-
Hu R, Zhou XJ, Li W. Computational Analysis of High-Dimensional DNA Methylation Data for Cancer Prognosis. J Comput Biol. 2022 08; 29(8):769-781.
-
Ridgway JP, Ajith A, Friedman EE, Mugavero MJ, Kitahata MM, Crane HM, Moore RD, Webel A, Cachay ER, Christopoulos KA, Mayer KH, Napravnik S, Mayampurath A. Multicenter Development and Validation of a Model for Predicting Retention in Care Among People with HIV. AIDS Behav. 2022 Oct; 26(10):3279-3288.
-
El-Shennawy L, Hoffmann AD, Dashzeveg NK, McAndrews KM, Mehl PJ, Cornish D, Yu Z, Tokars VL, Nicolaescu V, Tomatsidou A, Mao C, Felicelli CJ, Tsai CF, Ostiguin C, Jia Y, Li L, Furlong K, Wysocki J, Luo X, Ruivo CF, Batlle D, Hope TJ, Shen Y, Chae YK, Zhang H, LeBleu VS, Shi T, Swaminathan S, Luo Y, Missiakas D, Randall GC, Demonbreun AR, Ison MG, Kalluri R, Fang D, Liu H. Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2. Nat Commun. 2022 01 20; 13(1):405.
-
Giurcanu MC, Karrison TG. Nonparametric inference in the accelerated failure time model using restricted means. Lifetime Data Anal. 2022 01; 28(1):23-39.
-
Riedell PA, Hamadani M, Ahn KW, Litovich C, Brunstein CG, Cashen AF, Cohen JB, Epperla N, Hill BT, Im A, Inwards DJ, Lister J, McCarty JM, Ravi Kiran Pingali S, Shadman M, Shaughnessy P, Solh M, Stiff PJ, Vose JM, Kharfan-Dabaja MA, Herrera AF, Sauter CS, Smith SM. Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation. Br J Haematol. 2021 12; 195(5):757-763.
-
Schulte R, Hinson A, Huynh V, Breese EH, Pierro J, Rotz S, Mixon BA, McNeer JL, Burke MJ, Orgel E. Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia. Cancer Med. 2021 11; 10(21):7551-7560.
-
Schmiegelow K, Rank CU, Stock W, Dworkin E, van der Sluis I. SOHO State of the Art Updates and Next Questions: Management of Asparaginase Toxicity in Adolescents and Young Adults with Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2021 11; 21(11):725-733.
-
Manglaviti S, Brambilla M, Signorelli D, Ferrara R, Lo Russo G, Proto C, Galli G, De Toma A, Occhipinti M, Viscardi G, Beninato T, Zattarin E, Bini M, Lobefaro R, Massa G, Bottiglieri A, Apollonio G, Sottotetti E, Di Mauro RM, Trevisan B, Ganzinelli M, Fabbri A, de Braud FGM, Garassino MC, Prelaj A. Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology. Clin Lung Cancer. 2022 01; 23(1):e17-e28.
-
Balyasny S, Lee SM, Desai AV, Volchenboum SL, Naranjo A, Park JR, London WB, Cohn SL, Applebaum MA. Association Between Participation in Clinical Trials and Overall Survival Among Children With Intermediate- or High-risk Neuroblastoma. JAMA Netw Open. 2021 07 01; 4(7):e2116248.
-
Emens LA, Adams S, Barrios CH, Diéras V, Iwata H, Loi S, Rugo HS, Schneeweiss A, Winer EP, Patel S, Henschel V, Swat A, Kaul M, Molinero L, Patel S, Chui SY, Schmid P. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Ann Oncol. 2021 08; 32(8):983-993.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|